Cancer Gene CCND1's Dual Role: Fueling Inflammation in 'Zombie' Cells

Introduction

In a fascinating biological paradox, a gene long associated with cancer development has been found to play a critical role in cells that have deliberately stopped dividing to prevent malignancy. Scientists at Sanford Burnham Prebys Medical Discovery Institute, in collaboration with an international team, have uncovered that the gene CCND1, which encodes the protein cyclin D1, not only drives cell proliferation but also fuels chronic inflammation in senescent cells—cells in a state of irreversible growth arrest often referred to as 'zombie' cells. This finding, published on August 20, 2026, in Nature Aging, positions CCND1 as a potential therapeutic target for age-related diseases.

Key Details

The gene CCND1, responsible for producing cyclin D1, was initially identified in the 1990s for its role in promoting cancer when overexpressed.
Cyclin D1 normally regulates the cell cycle, pushing cells to divide. However, it is also highly expressed in senescent cells, which are non-proliferating and meant to prevent cancer.
Senescent cells halt division to prevent cancer and release inflammatory molecules to signal the immune system for removal.
The research confirmed that CCND1 is elevated in senescent cells and actively contributes to their inflammatory secretions, known as the senescence-associated secretory phenotype (SASP).
Cyclin D1 and its partner molecule, cyclin-dependent kinase 6 (CDK6), promote DNA damage, reinforcing the inflammatory tendencies of senescent cells.
In aged mice, CCND1 accumulation in liver cells correlated with increased inflammatory gene expression and DNA damage.
Mice genetically engineered to lack CCND1 showed reduced DNA damage and lower inflammatory gene expression in aged livers.
Treatment with palbociclib, a drug that inhibits cyclin D1-CDK6 interaction, reduced inflammation, suppressed frailty, and improved physical function in older mice.
Palbociclib is an FDA-approved drug for breast cancer, suggesting potential for repurposing in treating age-related inflammatory conditions.

Background

The gene CCND1 codes for cyclin D1, a protein crucial for regulating the cell cycle. In healthy cells, cyclin D1 acts as a signal to advance the cell cycle, prompting DNA replication and division. When this process goes awry and becomes hyperactive, it can lead to cancer. However, the presence of highly expressed cyclin D1 in senescent cells presented a puzzle. Senescent cells are characterized by their permanent exit from the cell cycle, a mechanism evolved to act as a barrier against cancer. This apparent contradiction led researchers to question the specific role of cyclin D1 in these non-proliferating cells.

Impact Analysis

The study meticulously investigated whether cyclin D1 played a distinct role in the inflammatory secretions of senescent cells, separate from its cell cycle functions. Initial analysis of publicly available sequencing data from various senescence models revealed that CCND1 was not only present but often more highly expressed than other known senescence markers. Subsequent laboratory experiments demonstrated that cyclin D1 actively contributes to the sustained release of inflammatory molecules characteristic of senescent cells. This inflammatory output, known as the senescence-associated secretory phenotype (SASP), is a major driver of chronic, low-grade inflammation that accumulates with age and is linked to numerous age-related diseases, including cardiovascular disease, arthritis, and neurodegeneration.

“It turned out that cyclin D1 and one of its partner molecules called cyclin-dependent kinase 6 reinforced these cells' inflammatory tendencies by promoting DNA damage,” stated lead author Adarsh Rajesh, PhD, a postdoctoral researcher at Cold Spring Harbor Laboratory and former member of the Adams lab.

The researchers then moved to a more complex model, examining aged mice. They observed that cyclin D1 accumulated in the livers of older mice, and these liver cells exhibited characteristics similar to those studied in vitro, with increased expression of genes involved in inflammatory molecule release. To ascertain the necessity of cyclin D1 in this process, they compared normal mice with those genetically engineered to be unable to produce cyclin D1. The aged livers of mice lacking cyclin D1 showed significantly less DNA damage and lower levels of inflammatory gene expression. This strongly suggested that cyclin D1 is a key mediator of age-related inflammation.

Broader Context

The accumulation of senescent cells and the resulting chronic inflammation are hallmarks of aging. While senescent cells initially serve a protective role by preventing damaged cells from becoming cancerous, their persistence and the inflammatory SASP they secrete contribute to tissue dysfunction and the development of age-related pathologies. The identification of cyclin D1 as a driver of this detrimental inflammatory process within senescent cells places it within the broader context of aging research, which increasingly focuses on targeting cellular senescence and inflammation to promote healthier lifespans. The study highlights the complex and sometimes counterintuitive roles that genes can play in different cellular contexts.

Future Outlook

The findings have significant implications for therapeutic strategies. The drug palbociclib, which inhibits the interaction between cyclin D1 and CDK6, was shown to not only dampen inflammation in aged mice but also to reduce frailty and improve physical function, including motor coordination and overall health status. Given that palbociclib is already approved by the FDA for treating certain types of breast cancer, its potential repurposing for age-related inflammatory diseases is a highly promising avenue. Researchers are optimistic about exploring this strategy further, aiming to develop treatments that could mitigate the effects of chronic inflammation and improve the quality of life for older adults.

Conclusion

This groundbreaking research elucidates a dual role for the CCND1 gene, linking its well-established function in cell proliferation and cancer to a newly discovered role in driving chronic inflammation in senescent cells. By uncovering how cyclin D1 promotes the detrimental SASP and contributes to age-related decline, the study provides a critical molecular target. The successful demonstration of therapeutic benefits using palbociclib in mice suggests a tangible path toward interventions that could combat age-related diseases by modulating inflammation, offering a hopeful outlook for healthier aging.